GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on bone

To cite this version:
Claire Philippe, Fabien Wauquier, Jean-Francois Landrier, Lauriane Bonnet, Elisabeth Miot-Noirault, et al.. GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on bone. Molecular Nutrition and Food Research, Wiley-VCH Verlag, 2017, 61 (2), pp.1600219. 10.1002/mnfr.201600219. hal-01506660

HAL Id: hal-01506660
https://hal.archives-ouvertes.fr/hal-01506660
Submitted on 12 Apr 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Research Article

GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on bone

Claire Philippe1,2,3, Fabien Wauquier1,2,3, Jean-François Landrier4,5, Lauriane Bonnet4,5, Elisabeth Miot-Noirault2,6, Gaël Y. Rochefort7, Jérémie Sadoine7, Mohamed Asrih8, François R. Jornayvaz8, Annick Bernalier9, Véronique Coxam1,2,3 and Yohann Wittrant1,2,3

1 INRA, UMR 1019, UNH, CRNH Auvergne, Clermont-Ferrand, France
2 Clermont Université, Université d’Auvergne, Unité de Nutrition Humaine, Clermont-Ferrand, France
3 Equipe Alimentation, Squelette et Métabolismes, Unité de Nutrition Humaine, Centre de Recherche INRA Auvergne Rhône Alpes, Site de Theix, 63122 Saint Genés Champanelle, France
4 INRA, UMR1260, Nutriments Lipidiques et Prévention des Maladies Métaboliques, Marseille, France
5 Faculté de Médecine, Université de la Méditerranée Aix-Marseille 1 et 2, Marseille, France
6 INSERM, UMR990, IMTV, Clermont-Ferrand, France
7 EA 2496 Pathologie, Imagerie et Biothérapies Orofaciales, UFR Odontologie, Université Paris Descartes and PIPA, PRES Sorbonne Paris Cité, Montrouge, France
8 Service d’Endocrinologie, Diabétologie et Métabolisme, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
9 INRA UR454, Unité de Microbiologie, Clermont-Ferrand, France

Scope: The stimulation of the free fatty acid receptor G-protein coupled receptor (GPR) 40 by GW9508 prevents bone loss by inhibiting osteoclast activity, both in vitro and in vivo. Here, we questioned whether the stimulation of the GPR40 receptor by dietary fatty acids may lead to the same beneficial effect on bone.

Methods and results: We investigated (i) the impact of a fatty acid enriched diet (high-fat diet [HFD]) on bone health in C57/BL6 female mice depending on (ii) the estrogen status (ovariectomy) and (iii) the genotype (GPR40+/+ or GPR40−/−). Bone mineral density (BMD), body composition, weight, inflammation and bone remodeling parameters were monitored. HFD decreased BMD in HFD-SH-GPR40+/+ mice but O VX failed to further impact BMD in HFD-OVX-GPR40+/+ mice, while additional bone loss was observed in HFD-OVX-GPR40−/− animals. These data suggest that when stimulated by fatty acid enriched diets GPR40 contributes to counteract ovariectomy-induced bone alteration. The sparing effect is supported by the modulation of both the osteoprotegerin/receptor activator of nuclear factor kappa-B ligand (OPG/RANKL) ratio in blood stream and the expression level of inflammatory markers in adipose tissues. Bone preservation by GPR40 stimulation is dependent on the presence of long-chain saturated fatty acids.

Conclusion: GPR40 contributes to counter ovariectomy-induced bone loss in a context of saturated fatty acid enrichment.

Keywords:
Free fatty acid receptor / GPR40 / High-fat diet / Nutrition / Osteoporosis

Additional supporting information may be found in the online version of this article at the publisher’s web-site

© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
1 Introduction

A growing body of data has revealed complex relationships between dietary lipids and the skeleton [1]. Depending on the type of fatty acids, the biological activity on bone may differ. Literature has mainly evidenced that high-fat diets (HFDs) negatively impact bone health. However, most of the studies have focused their investigations on hyper caloric diets enriched with saturated fatty acids in healthy groups without asking whether a beneficial effect could exist under certain circumstances. Regarding the unsaturated fatty acid family, the ω-6 family has been shown to enhance osteoporosis establishment while ω-3 fatty acids seem to preserve bone tissues [2–5]. These seemingly conflicting results have raised the idea that in some ways the modulation of the lipid intakes may represent a preventive opportunity for the management of bone complications. However, mechanisms of action are poorly understood and further investigations are required to develop innovative strategies regarding fat involvement in osteoporosis management.

About a decade ago, several groups demonstrated that the G-protein coupled receptor (GPR) 40 was able to interact with medium- to long-chain fatty acids and to transduce a specific signal across the cell membrane [6–11]. The role of GPR40 (also known as Free Fatty Acid Receptor-1) was mainly examined in beta-cells for its involvement in insulin secretion [12–14]. Later, GPR40 roles were discovered in taste buds [15], enteroendocrine cells [16], and in the brain [17, 18].

Recently, we demonstrated in vivo and in vitro the implication of this receptor in bone homeostasis [19–22]. GPR40⁻/⁻ mice were characterized by an osteopenic/osteoporotic phenotype when compared to wild-type (WT) littermates. In addition, phenotype onset was prevented in WT ovariectomized mice when a GPR40 synthetic agonist, GW9508, was given orally. We further demonstrated that prevention by GW9508 was driven by an inhibition of osteoclastogenesis in a GPR40 dependent way. This synthetic agonist was used to decipher the role of GPR40 and to avoid confounding parameters. However, since free fatty acids are natural ligands for GPR40, we further questioned the relevance of this receptor in an integrative approach investigating whether this fatty acid receptor may represent an innovative opportunity in the design of nutritional and therapeutic strategies to prevent bone loss in an ageing population.

2 Materials and methods

2.1 Ethics

All animal procedures were approved by the institution’s animal welfare committee (Comité d’Ethique en Matière d’Expérimentation Animale Auvergne: CEMEEA) and were conducted in accordance with the European guidelines for the care and use of laboratory animals (CE 80-12). Animals were housed in the animal facility of the INRA Research for Human Nutrition (Agreement N°: C6334514). Throughout the study, animals were housed in a controlled environment characterized by a 12:12 h light-dark cycle, 20–22°C, 50–60% relative humidity. Mice were kept one per plastic cage with free access to water. At the end of the protocol, blood was withdrawn from anesthetized animals. Then, animals were sacrificed by cervical dislocation and tissues were harvested, frozen, and stored prior to investigation.

2.2 Genotype

GPR40⁻/⁻ mice were obtained from AMGEN Inc. As described by Latour et al. [19], GPR40⁻/⁻ mice on a mixed C57BL/6/129 background were generated by homologous recombination in embryonic stem cells at Lexicon Genetics (The Woodlands, TX, USA). Exon 2 of the GPR40 gene was replaced with a LacZ gene. The mice were backcrossed onto the C57BL/6 strain over nine generations. Pups were screened by PCR performed on genomic DNA. WT littermates were used as controls.

2.3 Experimental design

In order to accustom the mice to the texture, animals were provided with free access to a standard growth powdered diet during an acclimatization period of 3 weeks from weaning (weeks 4–7). On week 7, mice were randomly divided into 16 groups (n = 12, individual cage), depending on the diet (six different diets), the type of surgery (SH or OVX) and the genotype (GPR40⁺/⁺ or GPR40⁻/⁻; Tables 1 and 2). From this point, mice were provided with their specific diet. On week 9, mice were sham-operated or ovariectomized to induce bone loss. Diets were delivered ad libitum for a total of 7 weeks including 5 weeks postsurgery (Fig. 1A and B). Briefly, every 48 h, each mouse received exactly 10 g of the diet in a small bowl (Fig. 1) to cover their needs (about 3–4 g per day; Fig. 4B). Food was changed every 48 h to minimize fatty acid oxidation. Once a week, the leftover food was weighted to evaluate the consumption of each mouse.

2.4 Ovariectomized mice

Mice were either sham-operated to mimic the side effects of the surgery or ovariectomized to induce an estrogen deprivation and a subsequent bone loss.

2.5 Diets

Diets were purchased from our experimental facility dedicated to the conception of animal diets (INRA UE0300, UPAE Unité de Préparation des Aliments Expérimentaux, Jouy-en-Josas, France). Compositions are summarized in Table 2. Diets were provided to the mice as powders and not as croquettes to avoid fatty acid heating and alteration during the croquettes’ production process. The fatty acid enrichment in
HFDs was obtained by a modulation of the corn starch content and in these cases, 42.18% of the calories were related to the fat content and 46.54% from the carbohydrate content. The total amount of calories was higher in the fatty acid enriched groups than in the control ones (464 kcal/100 g of diet versus 373 kcal/100 g of diet, respectively). The groups with fatty acid enrichment were isocaloric. This parameter was taken into account to allow group comparisons and to avoid any bias in the conclusions. The fatty acid profile of the HFD was designed to meet French dietary guidelines in terms of fatty acid ratios and set a reference point for the fatty acid content (Table 3). To test whether one fatty acid class may better activate GPR40 than another, selective enrichments of the diet were designed to produce saturated, omega-3, -6, and -9 HFDs (Table 2).

### 2.6 Bone mineral density analysis

After removing soft tissues, left femurs were placed in PBS with 10% formaldehyde at 4°C for 1 week. Bone mineral density (BMD) was measured using an eXplore CT 120 scanner (GE Healthcare, Canada). Acquisitions were performed with X-ray tube settings at 100 kV and 50 mA. We limited our investigation to the trabecular region of the distal metaphysis of the left femurs. ROI was set at 2000 µm height. Measurements started 300 µm in the proximal direction from the growth plate.

### 2.7 Body mass and composition

Mice were weighed every week throughout the experimental period and subjected to body composition analysis at the beginning and at the end of the protocol using QMR EchoMRI-900 system. Whole body fat and lean (excluding bone mass) mass were measured in living animals with no need of sedation.

### Table 2. Composition of HFDs

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Control</th>
<th>HFD</th>
<th>Saturated HFD</th>
<th>Omega-6 HFD</th>
<th>Omega-3 HFD</th>
<th>Omega-9 HFD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein</td>
<td>14.00</td>
<td>14.00</td>
<td>14.00</td>
<td>14.00</td>
<td>14.00</td>
<td>14.00</td>
</tr>
<tr>
<td>Sucrose</td>
<td>10.00</td>
<td>10.00</td>
<td>10.00</td>
<td>10.00</td>
<td>10.00</td>
<td>10.00</td>
</tr>
<tr>
<td>Dextrin (maltodextrin)</td>
<td>15.50</td>
<td>15.50</td>
<td>15.50</td>
<td>15.50</td>
<td>15.50</td>
<td>15.50</td>
</tr>
<tr>
<td>Cellulose</td>
<td>5.00</td>
<td>5.00</td>
<td>5.00</td>
<td>5.00</td>
<td>5.00</td>
<td>5.00</td>
</tr>
<tr>
<td>Corn oil</td>
<td>7.00</td>
<td></td>
<td>4.00</td>
<td>4.00</td>
<td>4.00</td>
<td>4.00</td>
</tr>
<tr>
<td>Rapasced oil</td>
<td></td>
<td>6.72</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunflower oil</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fish oil concentrated 22/60 TG (EPA/DHA)</td>
<td></td>
<td>0.48</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fish oil Omegavie DHA 70 TG QS ICE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olive oil</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20.00</td>
</tr>
<tr>
<td>L-cystine</td>
<td>0.18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Mineral mix (AIN-93M) Ca normal (0.5% per kg of diet)</td>
<td>3.50</td>
<td>3.50</td>
<td>3.50</td>
<td>3.50</td>
<td>3.50</td>
<td>3.50</td>
</tr>
<tr>
<td>Vitamins (AIN-93M) normal vitD (1000 UI diet)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>t-Butyl-hydroxyquinone</td>
<td>0.008</td>
<td>0.008</td>
<td>0.008</td>
<td>0.008</td>
<td>0.008</td>
<td>0.008</td>
</tr>
<tr>
<td>Corn starch (by difference)</td>
<td>43.56</td>
<td>26.56</td>
<td>26.56</td>
<td>26.56</td>
<td>26.56</td>
<td>26.56</td>
</tr>
<tr>
<td>Verification</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.mnf-journal.com
Figure 1. Scheme of experimental protocol design (A) and presentation of the food distribution mode (B). Acclimatization period (weeks 4–7); On week 7, mice were randomized into 16 groups (n = 12, individual cage) and provided with their specific diet (six different diets; two different genotypes; see Tables 1 and 2); On week 9, mice were ovariectomized or sham-operated to induce bone loss. Diets were delivered ad libitum for a total of 7 weeks including 5 weeks postsurgery.

Table 3. Validation of fatty acid composition of diets

<table>
<thead>
<tr>
<th>Fatty acid</th>
<th>Control (%)</th>
<th>HFD (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C12:0</td>
<td>—</td>
<td>0.18</td>
</tr>
<tr>
<td>C14:0</td>
<td>0.24</td>
<td>1.95</td>
</tr>
<tr>
<td>C16:0</td>
<td>15.29</td>
<td>25.71</td>
</tr>
<tr>
<td>C16:1 n-9</td>
<td>—</td>
<td>0.32</td>
</tr>
<tr>
<td>C16:1 n-7</td>
<td>—</td>
<td>2.41</td>
</tr>
<tr>
<td>C17:0</td>
<td>—</td>
<td>0.23</td>
</tr>
<tr>
<td>C17:1</td>
<td>—</td>
<td>0.2</td>
</tr>
<tr>
<td>C18:0</td>
<td>1.54</td>
<td>9.12</td>
</tr>
<tr>
<td>C18:1 n-9</td>
<td>27.07</td>
<td>36.51</td>
</tr>
<tr>
<td>C18:1 n-7</td>
<td>—</td>
<td>5.98</td>
</tr>
<tr>
<td>C18:2 n-6 cis</td>
<td>55.04</td>
<td>12.91</td>
</tr>
<tr>
<td>C20:1 n-9</td>
<td>—</td>
<td>0.34</td>
</tr>
<tr>
<td>C18:3 n-3</td>
<td>0.82</td>
<td>3.07</td>
</tr>
<tr>
<td>C20:5 n-3</td>
<td>—</td>
<td>0.6</td>
</tr>
<tr>
<td>C22:6 n-3</td>
<td>—</td>
<td>0.48</td>
</tr>
<tr>
<td>Verification</td>
<td>100%</td>
<td>99.53%</td>
</tr>
</tbody>
</table>

3 Results

3.1 Validation of the bone loss model

To validate ovariectomy-induced oestrogen deficiency, mice uteri were weighed and checked for atrophy. As expected, uterus mass of the ovariectomized animals was significantly lower than those isolated from sham-operated females (Fig. 2). Consistently, BMD was significantly decreased in Ctrl-OVX-GPR40+/+ mice compared to Ctrl-SH-GPR40+/+ (Fig. 3A). In addition, as previously described, BMD in GPR40−/− mice was significantly lower than in GPR40+/+ WT littermates (Fig. 3A), thus validating the consistency of both the OVX and the GPR40+/− mouse models, and allowing further investigation.

3.2 GPR40 limits bone loss induced by ovariectomy upon HFD

As shown in Fig. 3B, HFD-induced bone loss in HFD-SH-GPR40+/+ mice but OVX failed to further impact BMD in HFD-OVX-GPR40+/+ mice. In contrast, the absence of GPR40 revealed an additional BMD decrease in HFD-OVX-GPR40−/− mice (Fig. 3C). These data suggest that, when stimulated by fatty acid enriched diets, GPR40 contributes to counteract ovariectomy-induced bone alteration.
3.3 The protective effect of GPR40 is not related to mechanical protection

To ensure that GPR40 protective effects were not related to weight gain and subsequent mechanical loading due to an HFD, mice weight was monitored weekly throughout the experiment. Only ovariectomy significantly increased animals’ weight, whereas diet or genotype had no, or little effect on weight gain, suggesting that the absence of further bone loss in HFD-OVX-GPR40+/+ is not related to a modulation of the mechanical loading (Fig. 4A).

3.4 The absence of GPR40 leads to higher fat/lean mass ratio

EchoMRI data reveal that ovariectomy exerted a significant influence on body composition pattern with a decreased lean mass and an increased fat mass (Fig. 4C, D, and E). HFD had no particular effect on body composition, except in the absence of GPR40. Indeed, HFD-SH-GPR40−−/− mice showed a greater percentage of fat, while HFD failed to induce such a gain in HFD-SH-GPR40++/+ mice (Fig. 4D and E). This difference reveals that GPR40 may contribute to limit diet-induced fat gain and adipose tissue hypertrophy.

3.5 HFD causes increased systemic inflammation

To elucidate the role of HFD on bone behavior we questioned its impact on inflammatory status. Mice fed with the HFD exhibited both higher spleen weight and MCP-1 level in the serum (p < 0.0264 and p < 0.0001, respectively) independently of the oestrogen status or genotype (Fig. 5A and B, second panels). These results support a global negative impact of the HFD on inflammatory parameters that may contribute to explain, at least in part, the subsequent loss of BMD observed in HFD-SH mice. Ovariectomy or genotype had no significant impact on systemic inflammatory status.

3.6 Inflammation in adipose tissue is increased by ovariectomy and enhanced in the absence of GPR40

As aforementioned, ovariectomy did not significantly impact the systemic inflammatory status. However, locally, it increased the production of the proinflammatory cytokine MCP-1 by the inguinal adipose tissue (Fig. 5C, left and right panels). In contrast, the diet was ineffective. Regarding genotype influence, the absence of GPR40 mostly increased the production of TNF-α. Interestingly, when mice were ovariectomized and fed an HFD, the absence of GPR40 led to a massive increase of both TNF-α and MCP-1 cytokines, supporting an anti-inflammatory role for GPR40 at the adipose tissue level.

3.7 The absence of GPR40 leads to a greater production of RANKL

The analysis of OPG and RANKL expression, two major cytokines involved in bone tissue homeostasis, reveals that BMD level parallels OPG/RANKL ratio. These data suggest a key role for this molecular cross-talk between osteoblasts and osteoclasts in mediating ovariectomy, diet, and genotype influences on BMD (Fig. 6C, all panels). Interestingly, while no or little impact on OPG was observed in the HFD-OVX-GPR40−−/− group, the absence of GPR40 led to a remarkably increased level of RANKL (Fig. 6A and C, right panels). This
increase correlates with the observed alteration of bone and strongly supports that HFD no longer limits a greater bone resorbing cell differentiation in the absence of GPR40.

3.8 GPR40 bone sparing effect may rely on stimulation by saturated fatty acids

Since we demonstrated the role of GPR40 in mediating HFD positive influence in OVX-induced bone loss, we questioned the specificity on the receptor. The HFD combines different fatty acid groups. In order to decipher which one of these could be responsible for GPR40-related protection, fatty acid mixture composition was revised to allow diet enrichment either with saturated, ω-3, ω-6, or ω-9 fatty acids. Only the diet rich in saturated fatty acid showed similar effects to the so-called HFD diet while diets rich in ω-3, ω-6, or ω-9 failed to promote GPR40-related protection of bone tissue (Fig. 7). These data support a specificity for GPR40 toward saturated fatty acids that has never been reported before.
4 Discussion/conclusion

In this study, we demonstrated for the first time that GPR40 contributes to limit ovariectomy-induced bone loss when mice were fed an HFD. Limitation of bone loss in this model was associated with both a restrained production of proinflammatory cytokines by the white adipose tissue and a controlled level of RANKL. GPR40-related protection of bone tissue was dependent on the presence of saturated fatty acids. These results are consistent with previous published data obtained with the synthetic agonist GW9508.

We also confirmed that mice lacking GPR40 exhibited osteoporotic features [19]. As expected, oestrogen deficiency following ovariectomy was confirmed by uterine horns atrophy and led to bone loss independently of the diet or the genotype [23, 24]. Then, we provided evidence that HFD decreased BMD in HFD-SH-GPR40+/+ mice. This deleterious impact of the diet on bone parallels previous studies from Le’s and Faria’s groups showing that bone loss upon HFD was associated with an unbalanced osteoblast/osteoclast coupling and an increased of inflammatory status [25, 26]. In our hands, HFD increased MCP-1 level and spleen weight. Alteration of the OPG/RANKL ratio by the diet was also observed. Besides, bone loss observed in HFD-SH-GPR40+/+ mice occurred in the absence of weight gain supporting a metabolic deleterious effect of the diet uncovered by the absence of mechanical loading [27].

Interestingly, ovariectomy failed to further impact BMD in HFD-OVX-GPR40+/+ mice, while additional bone loss was observed in HFD-OVX-GPR40−/− animals. These data
support a positive role for GPR40 in bone sparing effect and strongly suggest that, when stimulated by fatty acid enriched diets, GPR40 contributes to counteract ovariectomy-induced bone alteration.

Ovariectomy-induced bone loss mainly relies on a rapid increase of osteoclast activity [28]. Besides, both osteoclast activity and differentiation are stimulated by proinflammatory conditions [29]. The presence or the absence of GPR40 did not significantly impact circulating level of MCP-1 or spleen weight. Therefore, while inflammation induced by HFD may account for the bone loss observed, the limitation of the O VX-induced bone loss by GPR40 cannot be explained by a modulation of the systemic inflammatory status. At the tissue level, ovariectomy increased TNF-α and MCP-1 expression by the inguinal white adipose tissue. This increase was enhanced by the absence of GPR40 and further strengthened when combined with HFD in the HFD-OVX-GPR40−/− group. MCP-1 released by adipocytes contributes to recruit macrophages that enhance a local inflammatory vicious cycle. Interestingly, this local macrophage recruitment may involve specific populations such as Ly6C monocytes that have the ability to migrate from bone marrow to inflammation sites, get activated and then return to bone marrow where they may contribute to initiate or enhance an inflammatory context with deleterious effect on bone health [30]. This concept is of particular interest and may explain, at least in part, the seemingly conflicting
Conclusions

GPR40 contributes to counteract ovariectomy-induced bone loss (Fig. 8). Despite this, a fatty acid receptor binding medium- to long-chain fatty acids contributes to limit excessive bone loss, this study may remain of mechanistic interest and our results rather support the relevance of pharmacologic approaches. Nevertheless, it is worth noting that GPR40 also binds medium-chain saturated fatty acids, such as myristic acid, that have been shown to limit the prevalence of metabolic complications [34, 35]. The relevance of such a class of lipids regarding bone health prevention remains to be investigated.

The authors would like to thank all the people who contributed to the ovariectomy procedures, the diet delivery, and the tissue sampling. They also thank Vincent Poitout and AMGEN for providing them the GPR40 mouse strain. They also express gratitude to Lisa Nucke for English grammar and syntax improvement.

The authors have declared no conflict of interest.

5 References


[21] Philippe, C., Wauquier, F., Leotoing, L., Coxam, V. et al., GW9508, a free fatty acid receptor agonist, specifically in-